MULTICENTRIC RETROSPECTIVE STUDY OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES TREATED WITH TARGET THERAPY – SEIFEM STUDY 2017 (AN UPGRATED)

Obinotuzumab is a third generation humanized anti-CD20 antibody, approved for the treatment of naïve CLL and FL and for the treatment of relapsed/refractory FL.

This observational retrospective clinical-epidemiological study aims to collect data from italian haematology centres where patients (aged over 18) with lymphoproliferative diseases are treated with obinutuzumab from its commercial availability (23/01/2015) to 31/12/2020. Exclusion criteria are: patients enrolled in clinical trials or in NPP, patients with active infections at the time of starting therapy, patients with other active neoplastic diseases.

Aims of the study

Primary

• Incidence of infectious complications (viral, bacterial, fungal)

Secondary

• Rate of patients receiving antiviral, antifungal, antibacterial prophylaxis
• Median time from the start of treatment and the onset of the infection
• Rate of discontinuation of the target drug because of infection
• Outcome of the infection
• Risk factors of infection